GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (LSE:AZN) » Definitions » Cyclically Adjusted Price-to-FCF

AstraZeneca (LSE:AZN) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted Price-to-FCF Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.17 48.06 60.81 62.36 57.36

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.90 62.58 58.91 57.36 -

Competitive Comparison of AstraZeneca's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.



AstraZeneca Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.444/130.0000*130.0000
=0.444

Current CPI (Mar. 2024) = 130.0000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.439 99.800 0.572
201409 0.746 100.000 0.970
201412 0.694 99.900 0.903
201503 -0.607 99.600 -0.792
201506 0.221 100.100 0.287
201509 0.624 100.200 0.810
201512 0.019 100.400 0.025
201603 0.492 100.400 0.637
201606 -0.456 101.000 -0.587
201609 0.267 101.500 0.342
201612 0.835 102.200 1.062
201703 -0.190 102.700 -0.241
201706 -0.050 103.500 -0.063
201709 1.119 104.300 1.395
201712 0.262 105.000 0.324
201803 -0.268 105.100 -0.331
201806 -0.174 105.900 -0.214
201809 0.121 106.600 0.148
201812 1.132 107.100 1.374
201903 -0.687 107.000 -0.835
201906 -0.058 107.900 -0.070
201909 0.469 108.400 0.562
201912 0.575 108.500 0.689
202003 -0.146 108.600 -0.175
202006 0.038 108.800 0.045
202009 0.657 109.200 0.782
202012 0.708 109.400 0.841
202103 0.801 109.700 0.949
202106 0.292 111.400 0.341
202109 0.515 112.400 0.596
202112 0.337 114.700 0.382
202203 1.395 116.500 1.557
202206 0.367 120.500 0.396
202209 1.030 122.300 1.095
202212 0.970 125.300 1.006
202303 0.878 126.800 0.900
202306 0.627 129.400 0.630
202309 1.158 130.100 1.157
202312 0.722 130.000 0.722
202403 0.444 130.000 0.444

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (LSE:AZN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AstraZeneca Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (LSE:AZN) Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (LSE:AZN) Headlines

From GuruFocus

AstraZeneca: Growth Is Still a Better Choice

By Nathan Aisenstadt 11-15-2023